Syndax Pharmaceuticals, a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, has hired Michael Meyers as Senior Vice President and Chief Development Officer. Dr Meyers will report to Briggs Morrison, Chief Executive, and become a member of the senior management team. He will be responsible for all aspects of clinical development of entinostat, Syndax's oral, small molecule that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing anti-tumour immune responses.
Most recently, Dr Meyers held a number of senior-level roles at Johnson & Johnson (J&J). Previously, he led the US Oncology Medical Affairs team at Aventis Pharmaceuticals, and worked in oncology clinical development at the Schering-Plough Research Institute. Dr Meyers served on the faculty at Memorial Sloan Kettering Cancer Center, specialising in clinical immunology and melanoma.
'With exciting opportunities to focus on multiple, new combination immuno-oncology therapies, it's an exceptional time to join Syndax,' he said.
